000167436 001__ 167436
000167436 005__ 20240229133539.0
000167436 0247_ $$2doi$$a10.3390/cancers13040644
000167436 0247_ $$2pmid$$apmid:33562775
000167436 0247_ $$2altmetric$$aaltmetric:121776285
000167436 037__ $$aDKFZ-2021-00340
000167436 041__ $$aeng
000167436 082__ $$a610
000167436 1001_ $$0P:(DE-He78)6d4d6a0e2d726f899086ca98cd560922$$aGies, Anton$$b0$$eFirst author$$udkfz
000167436 245__ $$aFecal Immunochemical Tests Detect Screening Participants with Multiple Advanced Adenomas Better than T1 Colorectal Cancers.
000167436 260__ $$aBasel$$bMDPI$$c2021
000167436 3367_ $$2DRIVER$$aarticle
000167436 3367_ $$2DataCite$$aOutput Types/Journal article
000167436 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1614341100_31487
000167436 3367_ $$2BibTeX$$aARTICLE
000167436 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000167436 3367_ $$00$$2EndNote$$aJournal Article
000167436 500__ $$a#EA:C120#LA:C070#
000167436 520__ $$aFecal immunochemical tests (FITs) are widely used for colorectal cancer (CRC) screening. The detection of early-stage cancer and advanced adenoma (AA), the most important premalignant lesion, is highly relevant to reducing CRC-related deaths. We aimed to assess sensitivity for the detection of CRC and AA stratified by tumor stage; number; size; histology of AA; and by location, age, sex, and body mass index (BMI).Participants of screening colonoscopy (n = 2043) and newly diagnosed CRC patients (n = 184) provided a stool sample before bowel preparation or CRC surgery. Fecal hemoglobin concentration was determined in parallel by nine different quantitative FITs among 94 CRC patients, 200 AA cases, and 300 participants free of advanced neoplasm. Sensitivities were calculated at original cutoffs and at adjusted cutoffs, yielding 93% specificity among all FITs.At adjusted cutoffs, UICC stage I cancers yielded consistently lower sensitivities (range: 62-68%) compared to stage II-IV cancers (range: 73-89%). An even stronger gradient was observed according to T status, with substantially lower sensitivities for T1 (range: 39-57%) than for T2-T4 cancers (range: 71-100%). Sensitivities for the detection of participants with multiple AAs ranged from 55% to 64% and were by up to 25% points higher than sensitivities for T1 cancers.FITs detect stage I cancers and especially T1 cancers at substantially lower sensitivities than more advanced cancer stages. Participants with multiple AAs were detected with slightly lower sensitivities than stage I cancers and with even higher sensitivities than T1 cancers. Further research should focus on improving the detection of early-stage cancers.
000167436 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000167436 588__ $$aDataset connected to CrossRef, PubMed,
000167436 650_7 $$2Other$$aadvanced neoplasia
000167436 650_7 $$2Other$$acolon cancer
000167436 650_7 $$2Other$$aearly detection
000167436 650_7 $$2Other$$afecal occult blood test
000167436 650_7 $$2Other$$aprevention
000167436 7001_ $$0P:(DE-He78)20dc4ad11ff465acf5b99f1e679e10b7$$aNiedermaier, Tobias$$b1$$udkfz
000167436 7001_ $$0P:(DE-He78)39ab513728727300b8bd91be7120b69d$$aGruner, Laura Fiona$$b2$$udkfz
000167436 7001_ $$0P:(DE-He78)c465139c8b95a919efed7d35ca83ca80$$aHeisser, Thomas$$b3$$udkfz
000167436 7001_ $$0P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aSchrotz-King, Petra$$b4$$udkfz
000167436 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b5$$eLast author$$udkfz
000167436 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers13040644$$gVol. 13, no. 4, p. 644 -$$n4$$p644 $$tCancers$$v13$$x2072-6694$$y2021
000167436 909CO $$ooai:inrepo02.dkfz.de:167436$$pVDB
000167436 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6d4d6a0e2d726f899086ca98cd560922$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000167436 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)20dc4ad11ff465acf5b99f1e679e10b7$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000167436 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)39ab513728727300b8bd91be7120b69d$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000167436 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c465139c8b95a919efed7d35ca83ca80$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000167436 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000167436 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000167436 9130_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000167436 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000167436 9141_ $$y2021
000167436 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2018$$d2020-09-11
000167436 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-09-11
000167436 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-09-11
000167436 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-09-11
000167436 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-09-11
000167436 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-09-11
000167436 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2020-09-11
000167436 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2020-09-11
000167436 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-09-11
000167436 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-09-11
000167436 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-09-11
000167436 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-09-11
000167436 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-09-11
000167436 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-09-11
000167436 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-09-11
000167436 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-09-11
000167436 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2018$$d2020-09-11
000167436 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2020-09-11
000167436 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-09-11
000167436 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x0
000167436 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x1
000167436 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000167436 980__ $$ajournal
000167436 980__ $$aVDB
000167436 980__ $$aI:(DE-He78)C120-20160331
000167436 980__ $$aI:(DE-He78)C070-20160331
000167436 980__ $$aI:(DE-He78)HD01-20160331
000167436 980__ $$aUNRESTRICTED